Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326850 | 0.89 | TAAR1 (0.47) | PDE4BPDE4DSNCATSHRNPC1 | |
| SCHEMBL3791461 | 0.88 | PDE4D (0.44) | PDE4BPDE4DSNCATSHRNPC1 | |
| SCHEMBL7911734 | 0.88 | PDE4D (0.44) | PDE4BPDE4DSNCAMAPTMEN1 | |
| SCHEMBL4326854 | 0.87 | PDE4D (0.48) | PDE4BPDE4DSNCATSHRNPC1 | |
| SCHEMBL4326556 | 0.86 | PDE4B (0.41) | PDE4BPDE4DSNCATSHRNPC1 | |
| SCHEMBL8057832 | 0.85 | PDE4D (0.49) | PDE4BPDE4DSNCAMAPTMEN1 | |
| SCHEMBL3790303 | 0.84 | MAPT (0.41) | PDE4BPDE4DNPC1MAPTSMN1; SMN2 | |
| SCHEMBL3467239 | 0.83 | PDE4B (0.41) | PDE4BPDE4DTSHRNPC1MAPT | |
| SCHEMBL7904582 | 0.83 | PDE4D (0.41) | PDE4BPDE4DSNCANR3C1 | |
| SCHEMBL8024594 | 0.83 | PDE4B (0.42) | PDE4BPDE4DTSHRNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2628727-A2 | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders | Decode Genetics EHF (IS) | 2013-08-21 | — | — | EP | disclosed |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DeCODE Genetics enf (IS) | 2012-08-23 | — | — | US | disclosed |
| EP-2222639-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | Decode Genetics EHF (IS) | 2010-09-01 | — | — | EP | disclosed |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | US | disclosed |
| WO-2009067621-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4D 7/4885SNCA 2358/4885 |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4D 7/4885SNCA 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.